Angiotensin II promotes the progression of DKD, and angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARB) have shown protective effects against DKD in experimental and clinical trials [1]. The gene discussed is ACE; the disease is diabetic kidney disease.